|
OSBPL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.19564424606278E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.83659976116246E-10 |
| Normal-vs-Stage2 |
7.770000E-04 |
| Normal-vs-Stage3 |
5.55480106356754E-11 |
| Normal-vs-Stage4 |
4.16049994456102E-09 |
| Stage1-vs-Stage2 |
9.282000E-02 |
| Stage1-vs-Stage3 |
1.278000E-01 |
| Stage1-vs-Stage4 |
1.312210E-01 |
| Stage2-vs-Stage3 |
1.232280E-02 |
| Stage2-vs-Stage4 |
1.540260E-02 |
| Stage3-vs-Stage4 |
7.457200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.73714425861272E-13 |
| Normal-vs-AfricanAmerican |
1.491680E-02 |
| Normal-vs-Asian |
4.17809999997409E-06 |
| Caucasian-vs-AfricanAmerican |
2.735700E-02 |
| Caucasian-vs-Asian |
3.057800E-01 |
| AfricanAmerican-vs-Asian |
2.162200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.16489995427571E-09 |
| Normal-vs-Female |
3.81999987197901E-11 |
| Male-vs-Female |
7.338800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.10550054958026E-10 |
| Normal-vs-Age(41-60Yrs) |
1.2823999973044E-08 |
| Normal-vs-Age(61-80Yrs) |
1.97360017217818E-10 |
| Normal-vs-Age(81-100Yrs) |
7.809700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.563800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.679400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.300600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.499200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.808400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.151000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.648240E-04 |
| Classical-VS-Follicular |
3.694400E-01 |
| Classical-VS-Other |
3.758000E-01 |
| Classical-VS-Normal |
5.10830266975404E-11 |
| Tall-VS-Follicular |
2.386000E-04 |
| Tall-VS-Other |
4.164000E-01 |
| Tall-VS-Normal |
4.02344824124157E-12 |
| Follicular-VS-Other |
3.340800E-01 |
| Follicular-VS-Normal |
4.43030000000233E-05 |
| Other-VS-Normal |
2.036900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.60319998890424E-09 |
| Normal-vs-N1 |
1.22819998615853E-09 |
| N0-vs-N1 |
1.921940E-02 |
|
|
